Viswanathan R, Rajhkowa S
Pharmatherapeutica. 1982;3(2):93-9.
Nineteen chronic schizophrenic in-patients were entered into a 12-week open study of intramuscular clopenthixol decanoate. Fourteen patients completed the full 12-week treatment period; 3 were withdrawn due to inadequate clinical response or untoward adverse effects, and 2 were discharged and lost to follow-up. Doses administered were in the range 200 to 400 mg, weekly or fortnightly. Patients were assessed weekly using the Brief Psychiatric Rating Scale (BPRS). Nurses' Observation Scale for In-patient Evaluation (NOSIE-30) and the Clinical Global Impression (CGI). Unwanted effects were recorded on a checklist. Statistically significant improvements in the overall mean scores were noted on the BPRS at every assessment and on the NOSIE-30 at every assessment except in Week 4. Unwanted effects were generally mild and they decreased during the study. The results suggest that clopenthixol decanoate is an effective, well-tolerated antipsychotic agent, suitable for the treatment of chronic, long-stay schizophrenic in-patients.
19名慢性精神分裂症住院患者参与了一项为期12周的癸酸氯哌噻吨肌肉注射开放性研究。14名患者完成了完整的12周治疗期；3名患者因临床反应不足或出现不良反应而退出；2名患者出院后失访。给药剂量为每周或每两周200至400毫克。每周使用简明精神病评定量表（BPRS）、住院患者评估护士观察量表（NOSIE - 30）和临床总体印象量表（CGI）对患者进行评估。不良事件记录在检查表上。每次评估时，BPRS的总体平均得分均有统计学意义的改善，除第4周外，NOSIE - 30在每次评估时也有改善。不良事件一般较轻，且在研究期间有所减少。结果表明，癸酸氯哌噻吨是一种有效且耐受性良好的抗精神病药物，适用于治疗慢性长期住院的精神分裂症患者。
